ClinicalTrials.Veeva

Menu

A Comparative Study to Evaluate a Novel Algorithm As a Diagnostic Aid for ADHD in Youth Ages 6-17.

M

MindTension

Status

Enrolling

Conditions

ADHD

Treatments

Device: MT1 Auditory startle response patterns analysis algorithm
Device: T.O.V.A. Continuous Performance Test

Study type

Interventional

Funder types

Industry

Identifiers

NCT06728969
2023-0000

Details and patient eligibility

About

This study aims to demonstrate the accuracy of the MT1 algorithm using the MindTension biometric sensor device as a diagnostic aid for healthcare providers in diagnosing ADHD in youth ages ≥ 6 to ≤17 years.

Full description

The study aims to demonstrate the accuracy of the MT1 algorithm. The output of the MT1 algorithm will be compared to a Gold Standard clinical diagnosis made by specialist clinician diagnosis supported by the Kiddie SADS Present and Lifetime semi-structured interview (K-SADS-PL) and norm-referenced measures of current ADHD symptom frequency and severity using the ADHD-RS-5 rating scale. Diagnosis will be scaled according to the Diagnostic and Statistical Manual of Mental Disorders- 5 (DSM-5) criteria, and made with agreement between two licensed specialists in ADHD (a Clinical Psychologist and a Psychiatrist).

Further to the above, demonstrate that the agreement between the MT1 output and the specialist clinician diagnosis will be non-inferior to the level of agreement between the clinician diagnosis with the Test of Visual Attention (TOVA) FDA cleared device.

Enrollment

120 estimated patients

Sex

All

Ages

6 to 17 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  1. Parent provision of signed and dated informed consent form
  2. Child stated willingness to comply with all study procedures and availability for the duration of the study
  3. Any gender, aged 6 to 17 years
  4. Stimulant naïve or willing to wash out of stimulant for 3 days (approximately 72 hours) prior to testing with biometric and performance devices (MindTension + TOVA)
  5. ADHD Group: Diagnosed with symptoms consistent with ADHD as determined by Mini Kid + an ADHD-RS score of 1.5SD above mean for age and sex
  6. Control group: No diagnosable disorder on the Mini kid, and an ADHD-RS score within 1SD of the mean for age and sex.

Exclusion criteria

  1. Current use of psychotropic medications that cannot be washed out in 3 days (approximately 72 hours)
  2. Known current seizure disorder (history of febrile seizure allowed).
  3. Presence of specific devices (e.g., cardiac pacemaker) that may interfere with the MindTension monitor
  4. IQ<70 by clinician judgment
  5. Meeting FULL criteria for current PTSD, GAD, MDD, or any lifetime diagnosis of ASD, Bipolar disorder, or psychotic disorder that was, in the opinion of the investigator, correctly obtained. May have symptoms of anxiety or dysthymia/depression not meeting criteria for a full disorder, or disorders such as simple phobia
  6. Deaf or hearing impaired, since this will make it difficult to hear and respond to the auditory stimuli.
  7. Inability to complete the assessments.
  8. Any other concerns in the judgment of the PI.

Trial design

Primary purpose

Diagnostic

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

120 participants in 2 patient groups

ADHD group
Experimental group
Description:
Subjects will be evaluated for ADHD using clinically established reference standard interviews and psychometric tools with demonstrated validity, including the K-SADS and ADHD-RS-5, in accordance with DSM-5 criteria. IQ will be estimated using two subtests of the WASI.
Treatment:
Device: T.O.V.A. Continuous Performance Test
Device: MT1 Auditory startle response patterns analysis algorithm
Non-ADHD group
Experimental group
Description:
Subjects will be evaluated using clinically established reference standard interviews and psychometric tools with demonstrated validity, including the K-SADS and ADHD-RS-5, in accordance with DSM-5 criteria. IQ will be estimated using two subtests of the WASI.
Treatment:
Device: T.O.V.A. Continuous Performance Test
Device: MT1 Auditory startle response patterns analysis algorithm

Trial contacts and locations

1

Loading...

Central trial contact

Beth Krone, PhD, MS; Jeffrey Newcorn, MD Professor

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems